The present Competitive Intelligence Report about Emerging Diabetes Drugs
provides a competitor evaluation in the field of novel molecules against a
series of novel targets being developed for treatment of type 1 or 2 diabetes
as of April 2011. Pharmacologic approaches include SGLT inhibitors,
glucokinase activators, 11beta-HSD1 inhibitors and many others. Purchase of
the downloadable pdf report includes a 6-month online access to the data of
the report and any updates since the publication date. Credentials to access
the database will be sent by e-mail and allow online work with the project
data to print or export an individual report.
The report includes a compilation of currently active projects in research and
development of novel molecules for treatment of type 1 and 2 diabetes. In
addition, the report lists company-specific R&D pipelines of emerging diabetes
drugs in R&D. Competitor projects are listed in a tabular format providing
information on:
Drug Codes,
Target / Mechanism of Action,
Class of Compound,
Company,
Product Category,
Indication,
R&D Stage and
additional comments with a hyperlink leading to the source of information.
Competitor Analysis: Emerging Diabetes Drugs published by La Merie Publishing in April 14, 2011. This report consists of 104 pages and the price starts from US $ 868.
The contents of this page may be different from the latest version. Please contact us for details.
